Matthew Scarpelli1, Justine Yang Bruce2,3, Lakeesha Carmichael4, Jens Eickhoff5,4, Jill Kolesar5,6, Scott Perlman5,7, Robert Jeraj1,5, Glenn Liu1,8,5. 1. Department of Medical Physics, Wisconsin Institute for Medical Research, University of Wisconsin, Room 1005, 1111 Highland Ave, Madison, WI, 53705, USA. 2. Division of Hematology/Oncology, Department of Medicine, Wisconsin Institute for Medical Research, University of Wisconsin, Room 7105, 1111 Highland Ave, Madison, WI, 53705, USA. jybruce@medicine.wisc.edu. 3. University of Wisconsin Carbone Cancer Center, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA. jybruce@medicine.wisc.edu. 4. Department of Biostatistics and Medical Informatics, K6/422 Clinical Science Center, University of Wisconsin, MC 4675, 600 Highland Ave, Madison, WI, 53792, USA. 5. University of Wisconsin Carbone Cancer Center, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA. 6. Department of Pharmacy, K4/554 Clinical Science Center, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA. 7. Department of Radiology, Clinical Science Center, University of Wisconsin, 600 Highland Ave, Box 3252, Madison, WI, 53792, USA. 8. Division of Hematology/Oncology, Department of Medicine, Wisconsin Institute for Medical Research, University of Wisconsin, Room 7105, 1111 Highland Ave, Madison, WI, 53705, USA.
Abstract
PURPOSE: This study utilizes FLT PET/CT imaging to characterize changes in tumor cell proliferation and vasculature during intermittent treatment with VEGR-TKI axitinib. METHODS: Patients with metastatic solid malignancies underwent 3-week treatment cycles with axitinib (7 and 5 mg BID for safety and pharmacodynamic cohorts, respectively). Cycles consisted of 2 weeks of treatment (dosing period) followed by a 1-week treatment break (washout period). Patients in the pharmacodynamic cohort had up to six FLT PET/CT scans (three scans in each cycle 1 and cycle 3) and had plasma VEGF concentrations measured at imaging timepoints. Changes in tumor SUVs and VEGF within and across drug cycles were investigated. RESULTS: Eight patients enrolled in the safety cohort where it was determined 7 mg axitinib was not tolerable due to severe adverse events, including three patients who experienced significant hypertension and thrombovascular effects. Sixteen patients enrolled in the pharmacodynamic cohort demonstrated significant decreases in SUVs and increases in VEGF during dosing periods. This was followed by significant increases in SUVs and decreases in VEGF during drug washout periods. No significant differences in SUVs or VEGF were found when comparing cycle 1 with cycle 3. A mixed effects model demonstrated significant negative correlation between SUV and VEGF. CONCLUSIONS: Response to axitinib included diminished FLT uptake during dosing periods followed by increased FLT uptake during drug washout periods. These changes were not different when comparing treatment cycle 1 versus cycle 3, suggesting that the pharmacodynamic effect of intermittent axitinib is similar across multiple drug cycles.
PURPOSE: This study utilizes FLT PET/CT imaging to characterize changes in tumor cell proliferation and vasculature during intermittent treatment with VEGR-TKI axitinib. METHODS:Patients with metastatic solid malignancies underwent 3-week treatment cycles with axitinib (7 and 5 mg BID for safety and pharmacodynamic cohorts, respectively). Cycles consisted of 2 weeks of treatment (dosing period) followed by a 1-week treatment break (washout period). Patients in the pharmacodynamic cohort had up to six FLT PET/CT scans (three scans in each cycle 1 and cycle 3) and had plasma VEGF concentrations measured at imaging timepoints. Changes in tumor SUVs and VEGF within and across drug cycles were investigated. RESULTS: Eight patients enrolled in the safety cohort where it was determined 7 mg axitinib was not tolerable due to severe adverse events, including three patients who experienced significant hypertension and thrombovascular effects. Sixteen patients enrolled in the pharmacodynamic cohort demonstrated significant decreases in SUVs and increases in VEGF during dosing periods. This was followed by significant increases in SUVs and decreases in VEGF during drug washout periods. No significant differences in SUVs or VEGF were found when comparing cycle 1 with cycle 3. A mixed effects model demonstrated significant negative correlation between SUV and VEGF. CONCLUSIONS: Response to axitinib included diminished FLT uptake during dosing periods followed by increased FLT uptake during drug washout periods. These changes were not different when comparing treatment cycle 1 versus cycle 3, suggesting that the pharmacodynamic effect of intermittent axitinib is similar across multiple drug cycles.
Authors: Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Hope S Rugo; Alison T Stopeck; Anil A Joy; Stephen Chan; Shailendra Verma; Anna Lluch; Katherine F Liau; Sinil Kim; Paul Bycott; Brad Rosbrook; Angel H Bair; Denis Soulieres Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Justine Yang Bruce; Peter Colin Scully; Lakeesha L Carmichael; Jens C Eickhoff; Scott B Perlman; Jill Marie Kolesar; Jennifer L Heideman; Robert Jeraj; Glenn Liu Journal: Cancer Chemother Pharmacol Date: 2015-05-29 Impact factor: 3.333
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Brian I Rini; May Garrett; Bill Poland; Janice P Dutcher; Olivier Rixe; George Wilding; Walter M Stadler; Yazdi K Pithavala; Sinil Kim; Jamal Tarazi; Robert J Motzer Journal: J Clin Pharmacol Date: 2013-03-28 Impact factor: 3.126
Authors: Matthew Scarpelli; Murtuza Rampurwala; Jens Eickhoff; Lakeesha Carmichael; Jennifer Heideman; Kimberly Binger; Jill Kolesar; Scott Perlman; Kim Harrow; Gary Dukart; Chris Liang; Robert Jeraj; Glenn Liu; Justine Yang Bruce Journal: Cancer Chemother Pharmacol Date: 2018-05-25 Impact factor: 3.333